LORAZOL

**LORAZOL** is Learmont Pharmaceuticals' named repurposed combination of **monobenzone** and **imiquimod** for late-stage melanoma. Imiquimod activates Toll-like receptor 7 to stimulate innate immune signaling, while monobenzone chemically modifies melanocyte and melanoma-associated proteins, promoting their recognition as foreign by the immune system. The intended combination effect is a melanoma-directed antitumor immune response. Learmont's public pipeline states that LORAZOL received FDA orphan-drug designation for late-stage melanoma and that a prior study of the monobenzone plus imiquimod combination had generated clinical-response observations; the company described plans for a confirmatory Phase 2 study beginning in 2020. ([embarkhc.com](https://www.embarkhc.com/learmont-pharmaceuticals/))

Brand names

LORAZOL

Other names

imiquimod + monobenzonemonobenzone + imiquimod